Aspirin for primary prevention: Yes or no?

Journal of Primary Health Care

Volumn 2, Issue 2, 2010, Pages 92-99

  Selak, Vanessa ^a   Raina Elley, C ^a   Wells, Sue ^a   Rodgers, Anthony ^b   Sharpe, Norman ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b GEORGE INSTITUTE FOR INTERNATIONAL HEALTH   (Australia)

^c National Heart Foundation of New Zealand   (New Zealand)

Author keywords

Aspirin; Cardiovascular disease; Cardiovascular risk; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT;

AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; FEMALE; GENERAL PRACTICE; HUMAN; MALE; META ANALYSIS; METHODOLOGY; MIDDLE AGED; PRACTICE GUIDELINE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; FAMILY PRACTICE; FEMALE; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS;

EID: 77955911202     PISSN: 11726164     EISSN: 11726156     Source Type: Journal    
DOI: 10.1071/hc10092     Document Type: Article

References (16)

1. World Health Organization. Global burden of disease. death and dALY estimates for 2004 by cause for WHO member states. Geneva: World Health Organization; 2009.
2. New Zealand Guidelines Group. new Zealand cardiovacsular guidelines handbook: a summary resource for primary care practitioners. 2nd ed. Wellington: Zealand Guidelines Group; 2009.
3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419-24.
4. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60.
5. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1990;121:293-8.
6. U.S. Preventive services Task Force. Aspirin for the prevention of cardiovascular disease: U. Preventive Task Force Recommendation statement. Ann int Med. 2009;150:396-404.
7. Brugts JJ, Yetgin T, Hoeks sE, Gotto AM, shepherd J, Westendorp RGJ, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta analysis of randomised controlled trials. BMJ. 2009;228:b2376.
8. Law MR, Morris JK, Wald nJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;228:b1665.
9. Law MR, Wald nJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 ranomised trials. BMJ. 2003;326:1427-34.
10. Law MR, Wald Rudnicka AR. quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic reivew and meta-analysis. BMJ. 2003;326:1423-9.
11. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi i, Tognoni G, Brown dL. Aspirin for the primary prevention of cardiovascular events in women and men. JAMA. 2006;295(3):306-13.
12. Belch J, MacCuish A, Campbell Cobbe s, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPAdAd) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
13. Riddell T, Wells S, Jackson R, Lee A-W, Crengle Bramley d, et al. Performance of Framingham cardiovascular risk scores by ethnic groups in new Zealand: PREdiCT CVd-10. NZ Med J. 2010;123(1309).
14. Elley CR, Robinson E, Kenealy T, Bramley d, drury PL. Derivation and validation of a new cardiovascular risk score for people with type 2 diabetes: the new Zealand diabetes Cohort study (dCs). Care. 2010;33(6).
15. new Zealand Guidelines Group. Evidence-based best practice guideline. The assessment and management of cardiovascular risk. new Zealand Guidelines Group; 2003.
16. British Hypertension society. statement on the use of aspirin. Fact File 01/2010, 2010.